453
Participants
Start Date
April 27, 2017
Primary Completion Date
June 30, 2021
Study Completion Date
October 15, 2024
pembrolizumab
Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
placebo
Normal saline solution administered as an IV infusion Q3W
best supportive care (BSC)
BSC will include pain management and management of other potential complications including ascites per local standards of care.
Chia-Yi Chang Gung Memorial Hospital ( Site 0133), Chiayi City
China Medical University Hospital ( Site 0131), Taichung
Beacon Hospital Sdn Bhd ( Site 0092), Petaling Jaya
Hospital Universiti Kebangsaan Malaysia ( Site 0093), Cheras
University Malaya Medical Centre ( Site 0091), Kuala Lumpur
National Cheng Kung University Hospital ( Site 0132), Tainan City
Beijing Cancer Hospital ( Site 0010), Beijing
The First Affiliated Hospital of Dalian Medical University ( Site 0022), Dalian
Jilin Province Cancer Hospital, Department of Chemotherapy ( Site 0002), Changchun
The First Hospital Of Jilin University ( Site 0001), Changchun
Fudan University Shanghai Cancer Center ( Site 0024), Shanghai
Zhongshan Hospital Fudan University ( Site 0012), Shanghai
Renji Hosp,Shanghai Jiao Tong University School of Medicine ( Site 0017), Shanghai
Jiangsu Cancer Hospital ( Site 0003), Nanjing
The 81st Hospital of PLA ( Site 0016), Nanjing
The First Affiliated Hospital of Soochow University ( Site 0025), Suzhou
Yangzhou No.1 People's Hospital ( Site 0023), Yangzhou
Nantong Tumor Hospital ( Site 0028), Nantong
Anhui Provincial Hospital ( Site 0032), Hefei
The First Affiliated Hospital of Anhui Medical University ( Site 0005), Hefei
The Second Affiliated Hospital of Anhui Medical University ( Site 0008), Hefei
Bengbu Medical College First Affiliated Hospital ( Site 0020), Bengbu
The First affiliated Hospital Zhejing University ( Site 0034), Hangzhou
Zhejiang Cancer Hospital ( Site 0011), Hangzhou
Fuzhou General Hospital of Nanjing Military Command ( Site 0019), Fuzhou
Hunan Cancer Hospital ( Site 0027), Changsha
The Third Xiangya Hospital of Central South University ( Site 0026), Changsha
Wuhan Tongji Hospital ( Site 0021), Wuhan
Hubei Cancer Hospital ( Site 0035), Wuhan
Guangdong General Hospital ( Site 0015), Guangzhou
The First People s Hospital of Foshan ( Site 0033), Foshan
Harbin Medical University Cancer Hospital ( Site 0007), Harbin
West China Hospital of Sichuan University ( Site 0030), Chengdu
The first affiliated Hospital of Xi an Jiaotong University ( Site 0014), Xi’an
Hong Kong Sanatorium Hospital ( Site 0053), Hong Kong
Pamela Youde Nethersole Eastern Hospital ( Site 0052), Hong Kong
Princess Margaret Hospital. ( Site 0051), Hong Kong
Seoul National University Hospital ( Site 0074), Seoul
Severance Hospital Yonsei University Health System ( Site 0073), Seoul
Asan Medical Center ( Site 0072), Seoul
Samsung Medical Center ( Site 0071), Seoul
Merck Sharp & Dohme LLC
INDUSTRY